Continuing Anticoagulation After Unprovoked VTE Lowers Recurrence but Raises Bleeding — Real‑World Target Trial Emulation Shows Net Clinical Benefit
Posted inCardiology Internal Medicine news

Continuing Anticoagulation After Unprovoked VTE Lowers Recurrence but Raises Bleeding — Real‑World Target Trial Emulation Shows Net Clinical Benefit

A large target‑trial emulation of US claims data found continued oral anticoagulation after ≥90 days for unprovoked VTE markedly reduced recurrent VTE and mortality, increased major bleeding, but produced an overall net clinical benefit that persisted through several years of follow‑up.
Cold Agglutinin Syndrome Secondary to Mycoplasma pneumoniae Infection in Adults: Insights from a Large French Observational Study
Posted inClinical Updates news Respiratory Specialties

Cold Agglutinin Syndrome Secondary to Mycoplasma pneumoniae Infection in Adults: Insights from a Large French Observational Study

A national French study reveals that cold agglutinin syndrome (CAS) develops about 10 days after Mycoplasma pneumoniae infection onset, often requiring ICU care and transfusions, with a generally favorable prognosis despite frequent venous thromboembolism and no clear benefit from glucocorticoid treatment.